1. Home
  2. AKRO vs NUV Comparison

AKRO vs NUV Comparison

Compare AKRO & NUV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • NUV
  • Stock Information
  • Founded
  • AKRO 2017
  • NUV 1987
  • Country
  • AKRO United States
  • NUV United States
  • Employees
  • AKRO N/A
  • NUV N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • NUV Trusts Except Educational Religious and Charitable
  • Sector
  • AKRO Health Care
  • NUV Finance
  • Exchange
  • AKRO Nasdaq
  • NUV Nasdaq
  • Market Cap
  • AKRO 2.0B
  • NUV 1.8B
  • IPO Year
  • AKRO 2019
  • NUV N/A
  • Fundamental
  • Price
  • AKRO $25.14
  • NUV $8.68
  • Analyst Decision
  • AKRO Strong Buy
  • NUV
  • Analyst Count
  • AKRO 8
  • NUV 0
  • Target Price
  • AKRO $46.83
  • NUV N/A
  • AVG Volume (30 Days)
  • AKRO 842.7K
  • NUV 464.9K
  • Earning Date
  • AKRO 02-27-2025
  • NUV 01-01-0001
  • Dividend Yield
  • AKRO N/A
  • NUV 3.96%
  • EPS Growth
  • AKRO N/A
  • NUV N/A
  • EPS
  • AKRO N/A
  • NUV N/A
  • Revenue
  • AKRO N/A
  • NUV N/A
  • Revenue This Year
  • AKRO N/A
  • NUV N/A
  • Revenue Next Year
  • AKRO N/A
  • NUV N/A
  • P/E Ratio
  • AKRO N/A
  • NUV N/A
  • Revenue Growth
  • AKRO N/A
  • NUV N/A
  • 52 Week Low
  • AKRO $15.32
  • NUV $7.86
  • 52 Week High
  • AKRO $37.00
  • NUV $9.08
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 41.89
  • NUV 50.08
  • Support Level
  • AKRO $21.34
  • NUV $8.60
  • Resistance Level
  • AKRO $28.94
  • NUV $8.71
  • Average True Range (ATR)
  • AKRO 1.38
  • NUV 0.07
  • MACD
  • AKRO -0.27
  • NUV 0.02
  • Stochastic Oscillator
  • AKRO 49.67
  • NUV 78.00

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

About NUV Nuveen Municipal Value Fund Inc.

Nuveen Municipal Value Fund Inc is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations issued by state and local government authorities or certain U.S. territories.

Share on Social Networks: